Related Experiment Video
Updated: Oct 4, 2026

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
Nanobodies as Versatile Next-Generation Biologics
Serge Muyldermans1,2, Jan Steyaert3,4
1Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium;
Abstract:
Nanobodies, also known as single-domain antibodies or variable domains of heavy-chain-only antibodies (VHHs), are the antigen-binding domains derived from heavy-chain-only antibodies that naturally occur in camelids. Since their discovery in the early 1990s, Nanobodies have attracted significant attention in the fields of biotechnology, structural biology, diagnostics, and therapeutics. Their unique structural and biochemical properties distinguish them from conventional antibodies and offer several practical advantages as versatile modular units in next-generation biologics. We discuss the most important and useful properties of Nanobodies, including their generation, physicochemical characteristics, manufacturability, stability, immunogenicity, antigen recognition capabilities, functional modulation, and engineering flexibility. We review the development and production of multivalent and multispecific Nanobody constructs; strategies to extend their in vivo half-life; and various functional fusions, including immunotoxins, imaging agents, and cellular therapies such as CAR T cell constructs.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Microorganisms in Medicine and Therapeutics

